Perspective · 30 Dec 2025
Conference abstractPublished 2 Jul 2012
Distinct perturbation of the translatome by the anti-diabetic drug metformin
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Reduced cancer incidence has been reported among type II diabetics treated with metformin. Laboratory models have demonstrated that metformin has anti-proliferative and anti-neoplastic effects associated with inhibition of mTORC1, but the sequellae of this inhibition are poorly understood. Here we show that metformin regulates gene expression at the level of mRNA translation, to an extent comparable to canonical mTOR inhibitors (rapamycin and PP242), and that its anti-proliferative activity involves selective translational suppression of mRNAs encoding cell cycle regulators via the mTORC1/4E-BP pathway. Thus metformin is a selective inhibitor of mRNA translation and thereby affects the proteome, suggesting applications in cancer prevention and treatment.
Subjects
Biochemistry & BiotechnologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Proteomics & Bioinformatics.
Commentary · 30 Dec 2025
Machine Learning in Bioinformatics Transforming Biological Data into Predictive Insights
Perspective · 30 Dec 2025
Post-Translational Modifications as Dynamic Regulators of Proteome Complexity and Cellular Function
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Proteomics & Bioinformatics
- SubjectBiochemistry & Biotechnology
- BylineArticles whose byline prints “Ola Larsson”
